Immucell Corp
ICCC- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000811641
No open-market purchases or sales by Immucell Corp insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $13.4M in total; no superinvestor holds it.
Q3 2024 vs. Q2 2024
How the institutions holding Immucell Corp changed between Q2 2024 and Q3 2024.
All holders in Q3 2024All holders in Q2 2024
| Measure | Q2 2024 | Of which not filed for Q3 2024 | Q3 2024 | Change |
|---|---|---|---|---|
| Holders | 28 | 1 | 22 | −5 |
| Shares | 1.15M | 13.8K | 1.15M | +20.2K (+1.8%) |
| Value | $5.56M | $66.8K | $4.27M | −$1.22M (−22.3%) |
1 institution that held it in Q2 2024 haven't filed for Q3 2024 yet. Not filing isn't selling, so the changes leave them out.
New holders (1)
Institutions that held Immucell Corp at the end of Q3 2024 but not at the end of Q2 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| BlackRock, Inc. | 14,312 | $52.0K | 0.00% |
Sold out (6)
Institutions that held Immucell Corp at the end of Q2 2024 and filed for Q3 2024 without it.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| Overbrook Management Corp | 32,857 | $159.4K |
| Citadel Advisors LLC | 23,746 | $115.2K |
| Susquehanna International Group, LLP | 20,844 | $101.1K |
| Wealth Effects LLC | 12,917 | $62.6K |
| Royal Bank of Canada | 123 | $1.00K |
| Innealta Capital, LLC | 1 | $5 |
Not filed for Q3 2024 yet (1)
Institutions that held Immucell Corp at the end of Q2 2024 and haven't filed a 13F for Q3 2024. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q2 2024 | Value, Q2 2024 |
|---|---|---|
| BlackRock Inc. | 13,764 | $66.8K |